

References

1. Davydova IV. *Novosti medicyny i farmacii – News of medicine and pharmacy* 2011;12:371–372 (in Russ).
2. Zaporozhan VM, Borys O.M. *Medyko-sotsialni problemy simi – Medical and social problems of the family* 2011;16(3):35–39 (in Ukrainian).
3. Mitchenko OI, Lutay MI. Kyiv, 2011. 48p (in Ukrainian).
4. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC. Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. *Circulation* 2009;120:1640–1645.
5. Alberti K, Zimmet P, Shaw J. International diabetes federation: a consensus on type 2 diabetes prevention. *Diabet. Med* 2007;24:451–463.
6. *American Diabetes Association. Diabetes Care* 2013;36(1):11–66.
7. Caren G, Frank B. Menstrual cycle irregularity and risk for future cardiovascular disease. *J Clin Endocr Metab* 2002;5:2013–2017.
8. de Groot PCM, Dekkers OM, Romijn JA, Dieben SWM, Helmerhorst FM. Coronary heart disease, stroke and the influence of obesity: a systematic review and meta-analysis. *Hum. Reprod* 2011;17:495–500.
9. Diamanti-Kandarakis E, Papavasiliou A. Molecular mechanisms of insulin resistance in polycystic ovary syndrome. *Tren. Mol. Med* 2006;12:324–332.
10. Diamanti-Kandarakis E, Papavassiliou A, Kandarakis S, Chrousos GP. Pathophysiology and types of dyslipidemia in PCOS. *Trends in Endocrinol. Metab* 2007;18:280–285.
11. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. *Endocr. Rev* 1997;18:774–800.
12. Ehrmann D, Liljenquist D, Kasza K. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. *J Clin Endocr Metab* 2006;91(1):48–53.
13. Ehrmann DA. Polycystic ovary syndrome. *N Engl J Med* 2005;352:1223–1236.
14. Finch D, Davis G, Bower J, Kirchner K. Effect of insulin on renal sodium handling in hypertensive rats. *Hypertension* 1990;15:514–518.
15. Glueck CJ, Papanna R, Ping Wang, Goldenber N, Sieve-Smith L. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. *Metab* 2003;52:908–915.
16. Holte J, Gennarelli G, Berne C, Bergh T, Lithell H. Elevated ambulatory day-time blood pressure in women with polycystic ovary syndrome: a sign of a pre-hypertensive state? *Hum Reprod* 1996;11:23–28.

17. Iyer SN, Raizada MK, Katovich MJ. AT1 receptor density changes during development of hypertension in hyperinsulinemic rats. *Clin Experim Hypertension* 1996;18:793–810.
18. Leslee J, Noel B, Ricardo A. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health — National Heart, Lung, and Blood Institute sponsored women's ischemia syndrome evaluation. *Clin Endocr Metab* 2008;93(4):1276–1284.
19. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Viigimaa M, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O'Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Waeber B, Williams B. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESC). *J Hypertens* 2007;25(6):1105–1187.
20. Moini A, Eslami B. Familial associations between polycystic ovarian syndrome and common diseases. *J Assist Reprod Genet* 2009;26:123–127.
21. Nichols M, Townsend N, Scarborough P. European cardiovascular disease statistics. 2012. p.10.
22. Norman RJ, Masters L, Milner CR, Wang JX, Davies MJ. Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. *Hum Reprod* 2001;16:1995–1998.
23. Pamidimukkala J, Jandhyala BS. Evaluation of hemodynamics, vascular reactivity and baroreceptor compensation in the insulin resistant Zucker obese rats. *Clin Experim Hypertension* 1996;18:1089–1104.
24. Phelan N, O'Connor A, Kyaw-Tun T, Correia N., Boran G, Roche HM, Gibney J. Lipoprotein subclass patterns in women with polycystic ovary syndrome (PCOS) compared with equally insulin-resistant women without PCOS. *J Clin Endocrinol Metab* 2010;95:3933–3939.
25. Renato P. Management of the metabolic syndrome and glucose intolerance in women with PCOS. *Nov Ins Path Treat PCOS* 2013:110–121.
26. Stein JH, Korcarz CE, Hurst RT, Lonn E, Kendall CB, Mohler ER, Najjar SS, Rembold CM. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society of Vascular Medicine. *J. Am. Society Echoc* 2008;21(2):93–111.
27. Talbott E, Clerici A, Berga S. Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study. *J Clin Epidemiol* 1998;51:415–422.

28. Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. *BMC Med* 2010;8:41–45.
29. Third report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. *Circulation* 2002;106:3143–3421.
30. Verma S, Bhanot S, Yao L, McNeil JH. Vascular insulin resistance in fructose-hypertensive rats. *Europ J Pharmacology* 1997;322:1–2.
31. Vribikova J. Cardiovascular risk factors in young Czech females with polycystic ovary syndrome. *Hum Reprod* 2003;18(5):980–984.
32. Yilmaz M, Bi'ri A, Bukan N, KarakoçA, Sancak B, Törüner F Paşaoğlu H. Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome. *Clin Endocrinol* 2005;20:258–263.